Literature DB >> 22119132

Stereoselective synthesis and QSAR study of cytotoxic 2-(4-oxo-thiazolidin-2-ylidene)-2-cyano-N-arylacetamides.

Riham F George1.   

Abstract

(2Z,5Z) 2-[(5-Arylidene-4-oxo-3-phenyl)-thiazolidin-2-ylidine]-2-cyano-N-arylacetamides 4a-l were stereoselectively prepared via condensation of aromatic aldehydes with 4-thiazolidinones 3a-c. The latters were obtained via electrophilic attack of phenylisothiocyanate on 2-cyano-N-arylacetamides 1a-c followed by reaction with chloroacetyl chloride under basic condition. Single crystal X-ray study of 3a allows good confirmation for the assigned structure. Additionally, 5-arylhydrazono analogs 5a-e were prepared via condensation of the appropriate diazonium salts with 4-thiazolidinones 3a,b. Many of the synthesized compounds exhibited promising antitumor properties against colon HCT116, breast MCF7 and liver HEPG2 cell lines. 3D-Pharmacophore modeling and QSAR analysis were combined to explain the observed antitumor properties.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22119132     DOI: 10.1016/j.ejmech.2011.11.006

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  3 in total

1.  A one-pot synthesis of bis(phenylimino)thiazolidines from ketene N,S-acetals and [Formula: see text],[Formula: see text]-diphenyloxalimidoyl dichloride.

Authors:  Issa Yavari; Nooshin Zahedi; Leila Baoosi; Stavroula Skoulika
Journal:  Mol Divers       Date:  2017-09-21       Impact factor: 2.943

2.  Crystal structures of two (Z)-2-(4-oxo-1,3-thia-zolidin-2-yl-idene)acetamides.

Authors:  Aleksei Galushchinskiy; Pavel Slepukhin; Konstantin Obydennov
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2017-11-10

3.  Cancer cells differentially activate and thrive on de novo lipid synthesis pathways in a low-lipid environment.

Authors:  Veerle W Daniëls; Karine Smans; Ines Royaux; Melanie Chypre; Johannes V Swinnen; Nousheen Zaidi
Journal:  PLoS One       Date:  2014-09-12       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.